3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
43
Phase 3
13
Phase 1
13
Phase 1/2
12
Phase NA
1
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Neoplasm Metastasis
1
Breast Neoplasms
1
Interventions
Saline Solution
10
Docetaxel
10
Bevacizumab
9
nilotinib
8
enzalutamide
8
Paclitaxel
8
Letrozole
8
Fentanyl
8
Everolimus
8
Cyclophosphamide
8
Carboplatin
8
Bupivacaine
8
Lidocaine
7
Sodium Chloride
6
Oxycodone
6
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
6
Erlotinib Hydrochloride
6
Dexamethasone
6
Capecitabine
6
Trastuzumab
5
Tobacco Use Cessation Devices
5
Surveys and Questionnaires
5
Nivolumab
5
Hydromorphone
5
Adalimumab
5
fludarabine
4
Zoledronic Acid
4
Tranexamic Acid
4
Tacrolimus
4
Rocuronium
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Has results
×
eribulin
×
Clear all
NCT01961544
2016-10-07
ESKIMO
Eisai Inc.
Phase 4
Completed
101 enrolled
6 charts